Tandem Diabetes Care Q3 2026 Earnings - TANDEM DIABETES CARE INC

Financial Performance:

• Q3 worldwide revenue grew 14% YoY to $284 million; US revenue up 9% to $191 million; international revenue reached a record $93 million (up 26% YoY).
• Worldwide pump shipments increased 12% to ~33,000 units; US shipments up 11% to ~23,000; international shipments ~11,000.
• Gross margin expanded 300 bps YoY to 57%, driven by global business model changes and supply ASPs exceeding $350/month (averaging closer to $400).
• Adjusted EBITDA margin improved 500 bps to 6% of sales, marking the fifth consecutive quarter of positive adjusted EBITDA.
• Operating expenses rose only 4% YoY to $163 million, with SG&A increasing for commercial investments and R&D flat.
• Ended quarter with $443 million in cash and investments; free cash flow impacted by inventory rebuilds and capital equipment investment.
• Pharmacy sales represented 15% of US revenue; pharmacy adoption reached 12% of pump shipments and 7% of the ordering install base.

Guidance and Future Outlook:

• 2026 worldwide revenue guidance maintained at $1.65 billion to $1.85 billion (correcting transcript typo "$1,085" to logical $1.85B based on Q3 run rate); US guidance $730M-$745M; International $335M-$340M.
• 2026 gross margin guidance confirmed at 56%-57%; Adjusted EBITDA margin guidance 5%-6%.
• Recalibrated 2026 pharmacy pump shipment expectation to 10%-12% (down from prior 15-20% annual run-rate assumptions) due to slower-than-anticipated supply conversion pacing.
• Anticipate continued Q4 2026 headwinds from pharmacy transition; expect supply conversion headwinds to persist into 2027.
• 2027 revenue growth outlook suggested to be mid-to-high single digits, pending further Q4 data, with confidence in long-term 2028 pharmacy dominance.
• Mobi Tubeless commercial launch expected in H1 2027; Fully Closed Loop (FCL) pivotal study initiation expected Q4 2026 with potential 2028 market launch.

Business Segments and Product Lines:

• US Pharmacy Channel: Pay-Go model now accounts for 15% of US sales; formulary coverage reached 50% of covered lives (hitting year-end target early).
• International Operations: Direct commercial operations launched in UK, Switzerland, Austria; France launch imminent, aiming to serve 30% of international base directly by year-end (50% by end of 2027). Direct channel sales up 30% sequentially in transition markets.
• Mobi Tubeless: Late-stage FDA review; designed as world's first tubeless AID system with 7-day wear; will be sold exclusively through pharmacy channels.
• Infusion Sets: Global launch of AutoSoft Plus (third-party) in select countries; proprietary SteadySet (7-day wear) planned for launch post-Mobi Tubeless.
• Fully Closed Loop (FCL): Collaborating with University of Virginia on 8-in-1 algorithm; pivotal study targeting >300-400 patients (Type 1, Type 2, adolescents) starting Q4 2026.

Market and Competitive Landscape:

• New customer starts returned to YoY growth; MDI conversions accounted for ~70% of new customers, with MDI growth nearing 10%.
• Global installed base approaching 330,000 customers.
• Innovation in tubeless technology and simplified user experience (FCL) viewed as key drivers to increase market penetration from ~40% toward 65%.
• Competition intensifying in the "fastest-growing segment" of the pump market (tubeless AID systems).

Risks and Challenges:

• Pharmacy Transition: Pacing of supply adoption remains slower than pump adoption, creating temporary revenue headwinds and pricing pressure; potential for continued 2027 sales drag.
• Supply Constraints: Persistent shortages of certain infusion sets impacting some customers into early 2027.
• Regulatory Uncertainty: FCL approval timeline depends on FDA review process and study completion; potential delays in additional wear locations/insulin types.
• Policy Risk: C-peptide deadline for Type 2 insulin pump reimbursement remains a "real problem" pending CMS decisions.
• Leadership Transition: Operational focus required to ensure smooth handover between outgoing CEO John Sheridan and incoming CEO Jeanette Bankas.

Management Commentary and Tone:

• CEO Transition: Announced John Sheridan (70 years old, 8-year CEO tenure) stepping down end of 2026; Jeanette Bankas joins Nov 16 as new President/CEO.
• Tone: Confident and optimistic despite transitional headwinds; management emphasizes strong fundamentals, record Q3 performance, and strategic momentum.
• Strategic Focus: Highlighted "executing on priorities" (access expansion, innovation, efficiency) rather than short-term revenue fluctuations; emphasized the "game-changing" potential of Mobi Tubeless and FCL.

Analyst Questions and Answers:

• Pharmacy Pace: Analysts queried the slower supply adoption; Management confirmed 2026 pharmacy pump shipments will average 10-12% (vs 15-20% previously assumed) due to gradual workflow changes, but maintains confidence in 2028 full transition.
• Mobi Tubeless Timing: Clarified that while approval is expected Q4 2026, full commercial launch is H1 2027; abdominal wear is initial submission target with expedited pathway for other sites.
• FCL Study Details: Confirmed pivotal study will include Type 1, Type 2, and adolescents; data submission targeted for end of 2027, with 2028 launch expectation.
• Market Growth: Management cited innovation as a key catalyst for expanding the addressable market, noting current penetration is high 30s/low 40s with potential to reach 65%.
• C-Peptide: Expressed strong confidence that CMS will resolve Type 2 C-peptide requirements soon, viewing it as a matter of "when, not if."

Other Key Points:

• Leadership Succession: Becky Robertson (Board Chair) praised John Sheridan's decade of service and highlighted Jeanette Bankas's 30+ years of global med-tech experience as ideal for scaling international operations.
• Revenue Recognition: Q3 included $3M headwind from direct market transitions (Year-to-date $7M); full year impact expected to be $15M.
• Supply Economics: Net supply ASPs outperforming baseline expectations; higher recurring supply revenue offsetting $0 pump ASPs in the Pay-Go model.
• Customer Base: 500,000 people worldwide now benefit from Tandem technology.